RegeneRx Biopharmaceuticals (RGRX) Stock Price, News & Analysis

Company Overview

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Key Stats

• Today's Range: $0.0014 to $0.0014
• 50-Day Range: $0.00 to $0.07
• 52-Week Range: $0.00 to $0.07
• Volume: N/A
• Average Volume: 29 shs
• Market Capitalization: $2,114.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGRX Stock Analysis - Frequently Asked Questions

How have RGRX shares performed this year?

RegeneRx Biopharmaceuticals' stock was trading at $0.0014 at the beginning of 2025. Since then, RGRX stock has increased by 0.0% and is now trading at $0.0014.
View the best growth stocks for 2025 here.

When did RegeneRx Biopharmaceuticals' stock split?

RegeneRx Biopharmaceuticals's stock reverse split on the morning of Monday, August 14th 2023. The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RegeneRx Biopharmaceuticals investors own include Fulcrum Therapeutics (FULC), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Biocept (BIOC) and Onconova Therapeutics (ONTX).

Company Calendar

• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGRX
• Previous Symbol: OTC:RGRX
• CUSIP: N/A
• CIK: 707511
• Web: www.regenerx.com
• Phone: (301) 208-9191
• Fax: 301-280-1996
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,510,000
• Free Float: 1,319,000
• Market Cap: $2,114.00
• Optionable: Not Optionable
• Beta: 2.81